These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 10394432)
1. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?]. Saiag P Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432 [No Abstract] [Full Text] [Related]
2. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance. Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942 [TBL] [Abstract][Full Text] [Related]
4. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group]. Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782 [No Abstract] [Full Text] [Related]
5. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? Schuchter LM J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612 [No Abstract] [Full Text] [Related]
6. The adjuvant treatment of malignant melanoma. Reintgen D; Kirkwood J J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
9. [To outwit melanoma with its own tricks]. Bischoff A MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255 [No Abstract] [Full Text] [Related]
10. The Sunbelt Melanoma Trial. McMasters KM Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897 [TBL] [Abstract][Full Text] [Related]
11. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. Moschos SJ; Kirkwood JM; Konstantinopoulos PA J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613 [No Abstract] [Full Text] [Related]
12. The promise of new technologies and therapies. Reintgen DS Cancer Control; 2002; 9(1):4-5. PubMed ID: 11907460 [No Abstract] [Full Text] [Related]
14. Does adjuvant vaccine therapy really have activity in malignant melanoma? Wheatley K; Ives NJ; Lorigan P J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569 [No Abstract] [Full Text] [Related]
15. Adjuvant interferon in the treatment of melanoma. Middleton MR Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281 [No Abstract] [Full Text] [Related]
16. A case of animal-type melanoma (or pigmented epithelioid melanocytoma?): an open prognosis. Vezzoni GM; Martini L; Ricci C Dermatol Surg; 2008 Jan; 34(1):105-9; discussion 110. PubMed ID: 18053035 [No Abstract] [Full Text] [Related]
17. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse. Gale DM; Kiley KE Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250 [TBL] [Abstract][Full Text] [Related]
18. Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C. Echternach M; Arndt S; Mattern D; Maier W; Richter B J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):E19-22. PubMed ID: 19344599 [No Abstract] [Full Text] [Related]